Published on September 27, 2013 at 11:01 AM
Etubics has received an approximately $1.5 million contract from the Small Business Innovation Research Development Center of the National Cancer Institute to manufacture its breast cancer immunotherapeutic, ETBX-021. The money will be used to generate the data required to support an IND application of ETBX-021 GMP product for a Phase I/II clinical trial.
ETBX-021 utilizes the Etubics Platform, which is stealth to the immune system and has the ability to deliver a long lasting active immune response against cancer targets, educating the immune system's T-cells to act as if the cancer was a simple virus, according to the company.
Etubics reported that preclinical studies have shown ETBX-021 can induce not only the traditional antibody response, but also potent cell-mediated immunity against HER2/neu tumors. Additionally, ETBX-021 prevented establishment of HER2/neu-expressing tumors and significantly inhibited progression of established tumors in mice models, the company said.
The award follows another grant Etubics received in July of approximately $1.03 million from the National Institute of Health to research and develop a therapeutic vaccine for HIV/human papilloma virus associated oropharyngeal and tonsillar malignancy.
This article was reprinted from Genetic Engineering & Biotechnology News (GEN) with permission from Mary Ann Liebert, Inc., publishers. Genetic Engineering & Biotechnology News (GEN) has retained its position as the number one biotech publisher around the globe since its launch in 1981. GEN publishes a print edition 21 times a year and has additional exclusive editorial content online, like news and analysis as well as blogs, podcasts, webinars, polls, videos, and application notes. GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.